U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review
-
Mon, 09-Mar-2020
- Posted by: Biocon Biologics
No Comments
Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 22-Feb-2020
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019
-
Thu, 20-Feb-2020
- Posted by: Biocon Biologics
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%
-
Thu, 23-Jan-2020
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour
-
Sat, 18-Jan-2020
- Posted by: Biocon Biologics
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake
-
Mon, 06-Jan-2020
- Posted by: Biocon Biologics
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer
-
Mon, 06-Jan-2020
- Posted by: Biocon Biologics
Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019
-
Wed, 11-Dec-2019
- Posted by: Biocon Biologics
Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally
-
Tue, 03-Dec-2019
- Posted by: Biocon Biologics
Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
-
Mon, 02-Dec-2019
- Posted by: Biocon Biologics
